

Clinical Development of Next-Generation EGFR Mutant Non-Small Cell Lung Cancer Treatment, JIN-A02



ONCOLOGY	Phase 1
Product Type	Small molecules
Indication	Non-small cell lung cancer (NSCLC) with EGFR mutations including C797S, acquired after EGFR-TKI treatment
Target	Epidermal Growth Factor Receptor (EGFR)
MoA(Mechanism of Action)	Selective and reversible binding to mutant EGFR including C797S
Competitiveness	<ul style="list-style-type: none"> - High selectivity and potency against C797S mutations including double and triple with ex19del or L858R/T790M - Potent tumor growth inhibition in in-vivo models and early clinical phase of double and triple mutations including C797S - High BBB permeability in in-vivo model and early clinical phase. - Excellent safety profile with sustained long-term tolerability
Development Stage	Phase 1
Route of Administration	Oral

Any unauthorized distribution or reproduction of this material is strictly prohibited.